Arca
Skip to content

Endometriosis

Drug research and approvals for endometriosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 161 studies of endometriosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 161
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 161 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
Dec 14, 2020A randomized, double-blind, open for active comparator, parallel-group, multicenter phase 2b study to access the efficacy and safety of three different doses…BAY 1817080BayerClosed
May 29, 2019A phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate…LINZAGOLIX/ ESTRADIOL-NORETHINDRONEOBSEVA S.AClosed
Nov 9, 2018Spirit extension: an international phase 3 open-label, single-arm, safety and efficacy extension study to evaluate relugolix co-administered with low-dose…RELUGOLIX/ ESTRADIOL-NORETHINDRONEMYOVANT SCIENCES GMBHClosed
May 24, 2018A randomized, double-blind, parallel-group, mutlicenter phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (bay 1002670)…VILAPRISAN (BAY 1002670)BayerClosed
Dec 28, 2017A study to evaluate safety and efficacy of elagolix alone or elagolix with hormonal add-back in subjects with endometriosis with associated moderate to severe…ELAGOLIX/ ESTRADIOL-NORETHINDRONE ACETATEAbbViePending
Nov 9, 2017Spirit 2: an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate relugolix administered with and without…RELUGOLIX/ ESTRADIOL-NORETHINDRONEMYOVANT SCIENCES GMBHOngoing
Nov 9, 2017Spirit 1: an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate relugolix administered with and without…RELUGOLIX/ ESTRADIOL-NORETHINDRONEMYOVANT SCIENCES GMBHClosed
Jul 24, 2017A phase 3 study to evaluate the safety and efficacy of elagolix in combination with estradiol/norethindrone acetate in subjects with moderate to severe…ELAGOLIX (ABT-620)/ ESTRADIOL-NORETHINDRONE ACETATEAbbVieClosed
Dec 19, 2014A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an…BAY 98-7196 (ANASTROZOLE-LEVONROGESTREL)BayerClosed
Oct 17, 2013Statins: a new therapeutic option for treatment of patients with endometriosisPRAVASTATIN/ UBIQUINOLDR ROBERT F CASPERPending

Medicines Authorised in the EU

Newest first
Jun 14, 2022Yseltylinzagolix cholineTheramex Ireland LimitedEMA ↗
Jul 16, 2021Ryeqorelugolix;estradiol;norethisterone acetateGedeon Richter Plc.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.